Abstract
Prostacyclin (2) is a natural product of blood vessels, synthetized predominantly in endothelium and released in minute amounts into circulation (3). Besides its potent antiplatelet activity (1,4, 6), prostacyclin is also a powerful vasodilator. The vasodilating properties were noticed already during first administration of prostacyclin to man (7), and were subsequently studied in detail in 10 subjects without evidence of coronary heart disease or cardiac failure (11, 12). Prostacyclin was infused in three dose levels (2, 5 and 10 ng/kg/min) leading to following effects:
-
1)
Distinct fall in peripheral and total pulmonary vascular resistances;
-
2)
Drop in intra-arterial blood pressure;
-
3)
Acceleration of the heart rate;
-
4)
Increase in muscle blood flow;
-
5)
Stroke volume, mean right atrial pressure and left ventricular end-diastolic pressure showed no significant changes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R.J. Gryglewski, Prostaglandins, platelets and atherosclerosis. CRC Series in Biochemistry 7: 291 (1980).
R.J. Gryglewski, S. Bunting, S. Moncada, R.J. Flower, J.R. Vane, Arterial walls are protected against deposition of platelet thrombi by a substance (Prostaglandin X) which they make from prostaglandins endoperoxides. Prostaglandins 12: 685 (1976).
R.J. Gryglewski, R. Korbut, A. Ocetkiewicz, Generation of prostacyclin by lungs in vivo and its release into arterial circulation. Nature 273: 765 (1978).
R.J. Gryglewski, A. Szczeklik, R. Nizankowski, Anti-platelet action of intravenous prostacyclin in man. Thrombos. Res. 13: 153 (1978).
A. Ollson, L.A. Carlson, Clinical, haemodynamic and metabolic effects of intraarterial infusion of prostaglandin E1 in patients with peripheral vascular disease. Adv. Prostagl. Thrombox. Res. 1: 429 (1976).
A. Szczeklik, R.J. Gryglewski, E. Nizankowska, R. Nizankowski, J. Musial, Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man. Prostaglandins, 16: 651 (1978).
A. Szczeklik, R.J. Gryglewski, R. Nizankowski, J. Musial, R. Pieton, J. Murk, Circulatory and antiplatelet effects of intravenous prostacyclin in healthy men. Pharmacol. Res. Commun. 10: 545 (1978).
A. Szczeklik, R. Nizankowski, S. Skawinski, J. Szczeklik, P. Gluszko, R.J. Gryglewski, Succesful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1: 1111 (1979).
A. Szczeklik, J. Szczeklik, R. Nizankowski, P. Gluszko, Prostacyclin for unstable angina. N. Engl. J. Med. 303: 881 (1980).
J. Szczeklik, J.S. Dubiel, M. Mysik, Z. Pyzik, R. Krol, R. Horzela, Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension. Br. Heart J. 40: 1397 (1978).
J. Szczeklik, A. Szczeklik, R. Nizankowski, Haemodynamic effects of prostacyclin in man. Adv. Prostagl. Thrombox. Res. 7: 769 (1980).
J. Szczeklik, A. Szczeklik, R. Nizankowski, Haemodynamic changes induced by prostayclin in man. Br. Heart J. 44: 254 (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Plenum Press, New York
About this chapter
Cite this chapter
Szczeklik, A., Gryglewski, R.J., Szczeklik, J., Nizankowski, R. (1984). Haemodynamic and Antihypertensive Effect of Prostacyclin. In: Strano, A. (eds) Thrombosis and Cardiovascular Disease. Advances in Experimental Medicine and Biology, vol 164. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8616-2_30
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8616-2_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-8618-6
Online ISBN: 978-1-4684-8616-2
eBook Packages: Springer Book Archive